March Biosciences and the art of avoiding friendly fire

A T-cell therapy aimed at T-cell cancer has an awkward problem: it can attack itself. March Biosciences is testing a CD5 design that sidesteps extra gene editing - and puts manufacturing at the heart of the medicine.